Bayer AG and Johnson & Johnson (JNJ, $136.36) to settle blood thinner Xarelto litigation
According to court documents released on Monday, the German pharmaceutical multinational, Bayer AG, and the American pharmaceutical major, Johnson & Johnson, have finally agreed to settle more than 25,000 U.S. lawsuits over their best-selling blood thinner Xarelto, for a total of $775 million.
Although Bayer and J&J are yet to admit liability under the agreement, the settlement resolves all the pending U.S. lawsuits over Xarelto. The fines would be equally split by both companies, as they jointly developed the drug. Plaintiffs accused the companies of failing to sufficiently notify patients on the risk of uncontrolled bleeding.
Bayer had jointly developed Xarelto with J&J’s Janssen Pharmaceuticals unit, which sells the blood clot preventer under a licensing agreement in the United States.
Xarelto emerged as Bayer’s best-selling drug in 2018 and contributed 3.6 billion euros ($4.07 billion) in revenue to the German group’s pharmaceutical business. J&J reported that Xarelto’s total sales in 2018 amounted to $2.47 billion.
JNJ in -0.62% downward trend, falling for three consecutive days on September 15, 2025
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where JNJ declined for three days, in of 304 cases, the price declined further within the following month. The odds of a continued downward trend are .
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for JNJ moved out of overbought territory on September 05, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 37 similar instances where the indicator moved out of overbought territory. In of the 37 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The Moving Average Convergence Divergence Histogram (MACD) for JNJ turned negative on August 26, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at .
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on September 11, 2025. You may want to consider a long position or call options on JNJ as a result. In of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where JNJ advanced for three days, in of 346 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 248 cases where JNJ Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.444) is normal, around the industry mean (9.489). P/E Ratio (18.994) is within average values for comparable stocks, (23.731). Projected Growth (PEG Ratio) (1.023) is also within normal values, averaging (1.762). Dividend Yield (0.029) settles around the average of (0.028) among similar stocks. P/S Ratio (4.751) is also within normal values, averaging (3.430).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. JNJ’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 80, placing this stock better than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an investment holding company with interests in health care products
Industry PharmaceuticalsMajor
Advertisement